Brief: Interpace Biosciences Q4 Revenue USD 9.224 Million
30/03/2026 21:01
Mar 30 (Reuters) - Interpace Biosciences Q4 operating income USD 1.577 million. Q4 gross profit USD 6.044 million Q4 operating expenses USD 4.467 million Q4 net income USD 22.657 million
Recent news on Interpace Biosciences
See all newsBrief: Interpace Biosciences Announces Reverse Stock Split To Support Proposed Nasdaq Uplisting
Interpace Biosciences Q2 revenue falls despite growth in thyroid business
Brief: Interpace Biosciences Q2 Revenue USD 9.131 Million
Interpace Biosciences Q1 revenue falls
Brief: Interpace Biosciences Q1 Revenue USD 9.032 Million